Photocure

Less than 1K followers

PHO

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Photocure is a medical technology company. The company specializes in solutions for photodynamic technology. The solutions are used to treat diseases that have caused bladder cancer and HPV. The main markets are in dermatology and oncology, where the products are used by hospitals and research institutes on a global level. The company was founded in 1993 and is headquartered in Oslo, Norway.

Market cap

-

Turnover

-

Revenue

525.39M

EBIT %

3.88 %

P/E

-

Dividend yield-%

-

Financial calendar

5.5

2025

General meeting '25

8.5

2025

Interim report Q1'25

30.7

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Regulatory press release2/28/2025, 2:51 PM

Photocure ASA - Major shareholding disclosure

Regulatory press release2/28/2025, 2:05 PM

PHO: NOTIFICATION OF MAJOR HOLDINGS

Regulatory press release2/19/2025, 7:00 AM

Photocure ASA: Results for the fourth quarter of 2024

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release2/19/2025, 7:00 AM

Photocure ASA: Results for the fourth quarter of 2024

Regulatory press release2/17/2025, 4:00 PM

News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared

Press release2/17/2025, 4:00 PM

News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared

Regulatory press release2/17/2025, 6:30 AM

Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025

Press release2/17/2025, 6:30 AM

Photocure: Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025

Regulatory press release2/12/2025, 1:27 PM

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2024 financial results

Regulatory press release2/12/2025, 1:27 PM

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2024 financial results

Regulatory press release1/16/2025, 7:46 AM

Photocure ASA: Transactions made under share buyback program

Regulatory press release1/16/2025, 7:46 AM

Photocure ASA: Transactions made under share buyback program

Regulatory press release1/13/2025, 7:00 AM

Photocure ASA: Transactions made under share buyback program

Regulatory press release1/13/2025, 7:00 AM

Photocure ASA: Transactions made under share buyback program

Regulatory press release1/5/2025, 7:47 AM

Photocure ASA: Transactions made under share buyback program

Regulatory press release1/5/2025, 7:47 AM

Photocure ASA: Transactions made under share buyback program

Regulatory press release12/23/2024, 7:02 AM

Photocure ASA - Share option grant

Regulatory press release12/23/2024, 7:02 AM

Photocure ASA - Share option grant

Regulatory press release12/19/2024, 7:02 AM

Photocure ASA: Initiation of a share buyback

Regulatory press release12/19/2024, 7:02 AM

Photocure ASA: Initiation of a share buyback

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.